Ocrelizumab: Neutropenia and off lable use.
In: Reactions Weekly, Jg. 2007 (2024-05-15), Heft 1, S. 281-281
serialPeriodical
Zugriff:
Two case reports were described in which patients developed neutropenia while receiving ocrelizumab for relapsing-remitting multiple sclerosis (MS). One patient, a woman, also received off-label use of ocrelizumab. In both cases, the development of neutropenia was attributed to ocrelizumab. The patients were treated with antibiotics and filgrastim, and their neutrophil counts normalized. Ocrelizumab treatment was discontinued, and alternative therapies were planned. [Extracted from the article]
Titel: |
Ocrelizumab: Neutropenia and off lable use.
|
---|---|
Zeitschrift: | Reactions Weekly, Jg. 2007 (2024-05-15), Heft 1, S. 281-281 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 0114-9954 (print) |
DOI: | 10.1007/s40278-024-58841-8 |
Schlagwort: |
|
Sonstiges: |
|